Uveal melanoma (UM) is the most common primary intraocular malignancy in adults with an annual incidence of 4 to 10 per million in the white population. The 5-year overall survival (OS) rate is approximately 70% to 80%. Up to 50% of patients with UM develop metastases, usually after a long disease-free interval (2-5 years). If metastatic disease is present, the prognosis is dismal with a 1-year OS rate of 10% to 40%. Currently, no effective systemic treatment improving OS is available for patients with metastatic UM, nor has any adjuvant treatment shown survival benefit.
Our research group and others have performed several prospective dendritic cell (DC) vaccination studies in patients with cutaneous melanoma showing little toxicity and promising immunologic and clinical results. [...]

doi.org/10.1016/j.ophtha.2016.06.027, hdl.handle.net/1765/95900
Department of Clinical Genetics

Bol, K., van den Bosch, T., Schreibelt, G., Mensink, H., Keunen, J., Kiliç, E., … de Vries, J. (2016). Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 123(10), 2265–2267. doi:10.1016/j.ophtha.2016.06.027